8-K
filed June 21, 2023, 7:59 PM ET
ticker EYPT
CIK 0001314102
other material
confidence high
sentiment neutral
materiality 0.65
Stockholders approve 2023 Long-Term Incentive Plan authorizing up to 3.5M new shares
EyePoint, Inc.
- All eight director nominees elected; each received >99% of votes cast (excluding broker non-votes).
- 2023 Long-Term Incentive Plan approved (21.9M for, 3.7M against) authorizing 3.5M new shares plus shares from prior plans.
- Non-binding say-on-pay approved with 25.4M for (99.2% of votes cast).
- Deloitte & Touche ratified as auditor for FY2023: 29.6M for, 138k against.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
EyePoint, Inc. shareholders approved Election of Directors.
- Proposal
- director election
- Outcome
- passed
Exact text from the filing
Proposal No. 1. Election of Directors The Company’s stockholders elected the following directors to the Board, each to serve until the Company’s 2024 Annual Meeting of Stockholders or until such person’s successor is duly elected and qualified. The voting on this proposal is set forth below: Vote Type Vote Results Göran Ando, M.D. For 25,523,018 Withheld 183,203 Broker Non-Votes 4,009,236 Nancy S. Lurker For 25,578,006 Withheld 128,215 Broker Non-Votes 4,009,236 John B. Landis, Ph.D. For 25,578,624 Withheld 127,597 Broker Non-Votes 4,009,236 David R. Guyer, M.D. For 25,562,931 Withheld 143,290 Broker Non-Votes 4,009,236 Wendy F. DiCicco For 25,570,654 Withheld 135,567 Broker Non-Votes 4,009,236 Ye Liu For 25,576,789 Withheld 129,432 Broker Non-Votes 4,009,236 Anthony P. Adamis For 25,568,829 Withheld 137,392 Broker Non-Votes 4,009,236 Karen Zaderej For 25,632,878 Withheld 73,343 Broker Non-Votes 4,009,236
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
EyePoint, Inc. shareholders approved Non-Binding Advisory Vote on Named Executive Officer Compensation.
- Proposal
- say on pay
- Outcome
- passed
Exact text from the filing
Proposal No. 3. Non-Binding Advisory Vote on Named Executive Officer Compensation The Company’s stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. The voting on this proposal is set forth below: Vote Type Vote Results For 25,419,375 Against 206,043 Abstain 80,803 Non Votes 4,009,236
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
EyePoint, Inc. shareholders approved 2023 Long-Term Incentive Plan.
- Proposal
- equity plan
- Outcome
- passed
Exact text from the filing
Proposal No. 2. 2023 Long-Term Incentive Plan The Company’s stockholders approved the EyePoint Pharmaceuticals, Inc. 2023 Long-Term Incentive Plan. The voting on this proposal is set forth below: Vote Type Vote Results For 21,899,109 Against 3,738,891 Abstain 68,221 Non Votes 4,009,236
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
EyePoint, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-12-31 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-12-31
Exact text from the filing
Proposal No. 4. Ratification of Appointment of Independent Registered Public Accounting Firm The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The voting on this proposal is set forth below: Vote Type Vote Results For 29,572,517 Against 138,031 Abstain 4,909 Non Votes 0
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.